Nicotinamide Mononucleotide
AssetAlso NMN
NAD+ precursor supplement that boosts cellular NAD+ levels and supports mitochondrial metabolism
- Stage
- Phase 1
- Modality
- Supplement
- Target
- Mitochondrial biogenesis (PGC-1α)
- 2
- Indications
- 5
- Trials
- 2
- Developers
Indications
2Enhance immune function
Phase 1, Unknown, NCT05984550, clinicaltrials.gov, 7 Oct 2026
Aging
Human trials, Completed, NCT04823260, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners2
- Trials5
- Evidence for its targets4
- Competitors12
- Aging relevance3
- Signals15
Every asset’s record: target, stage, trials and the evidence behind it.